[Federal Register Volume 59, Number 146 (Monday, August 1, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-18680]


[[Page Unknown]]

[Federal Register: August 1, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Conference on Feasibility of Genetic Technology to Close the HIV 
Window in Donor Screening; Notice of Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA), Office of the 
Commissioner, is sponsoring a public meeting to evaluate the 
feasibility and utility of gene amplification techniques to enhance 
viral detection in the seronegative ``window'' phase of human 
immunodeficiency virus (HIV) infection.
DATES: The public meeting will be held on Monday, September 26, 1994, 7 
a.m. to 4 p.m. through Wednesday, September 28, l994, 12 m.

ADDRESSES: The public meeting will be held at the Holiday Inn-Silver 
Spring, 8777 Georgia Ave., Silver Spring, MD.

FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Food and Drug 
Administration, Office of Health Affairs (HFY-20), 5600 Fishers Lane, 
Rockville, MD 20857, 301-443-1382, FAX 301-443-0232. Those persons 
interested in attending the meeting should mail their registration to 
Nicholas P. Reuter (address above). Registration should include name, 
title, organization, address, and telephone number and/or fax number. 
There is no charge for this meeting, but advance registration is 
required and early registration is encouraged due to seating 
limitations. The cutoff date for registration is August 26, l994.

SUPPLEMENTARY INFORMATION: Several novel approaches have been described 
for the detection of genetic sequences by amplification. Although these 
techniques offer high sensitivity for detection, problems of 
nonspecificity, reproducibility and reduced throughput have hampered 
their use in routine diagnosis. The program is designed to assess the 
current status of technology development and readiness for applications 
to donor screening. The procedural and economic aspects of implementing 
these techniques will also be discussed.

    Dated: July 26, 1994.
 Michael R. Taylor,
 Deputy Commissioner for Policy.
[FR Doc. 94-18680 Filed 7-29-94; 8:45 am]
BILLING CODE 4160-01-F